Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Jenner

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|November 17, 2006
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysisPing Wu, Faith E Davies, Clive Horton, et al.
Cancer Immunology, Immunotherapy : CII|May 19, 2015
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical studyKaty J McCann, Rosemary Godeseth, Lindsey Chudley, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcomeNicholas J Dickens, Brian A Walker, Paola E Leone, et al.
Leukemia & Lymphoma|December 28, 2020
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experienceNadjoua Maouche, Bhuvan Kishore, Matthew W Jenner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implicationsPaola E Leone, Brian A Walker, Matthew W Jenner, et al.
Annals of Hematology|April 3, 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaEvangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.
British Journal of Haematology|December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trialMatthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.
Eclinicalmedicine|August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialJohn R Jones, David A Cairns, Tom Menzies, et al.
Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|November 17, 2006
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysisPing Wu, Faith E Davies, Clive Horton, et al.
Cancer Immunology, Immunotherapy : CII|May 19, 2015
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical studyKaty J McCann, Rosemary Godeseth, Lindsey Chudley, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcomeNicholas J Dickens, Brian A Walker, Paola E Leone, et al.
Leukemia & Lymphoma|December 28, 2020
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experienceNadjoua Maouche, Bhuvan Kishore, Matthew W Jenner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implicationsPaola E Leone, Brian A Walker, Matthew W Jenner, et al.
Annals of Hematology|April 3, 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaEvangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.
British Journal of Haematology|December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trialMatthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.
Eclinicalmedicine|August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialJohn R Jones, David A Cairns, Tom Menzies, et al.
Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Pageof 4